Gamboa, Jorge L.
Mambungu, Cindy A.
Clagett, Adrienne R.
Nian, Hui
Yu, Chang
Ikizler, T. Alp
Brown, Nancy J.
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (K23DK100533)
National Center for Research Resources (1UL-1RR024975, 1UL-1RR024975, 1UL-1RR024975)
Article History
Received: 17 May 2022
Accepted: 30 April 2023
First Online: 11 May 2023
Declarations
:
: All the study participants had given written informed consent before enrollment. Prior to the initiation of the study, we obtained approval from Vanderbilt Institutional Review Board (IRB #131602). This study was conducted in accordance with the Declaration of Helsinsky.
: Not applicable.
: Shire/Takeda provided icatibant for the study through an Investigator Initiated Research Support grant. Drs. Brown and Gamboa serve as consultants to Pharvaris. Dr. Brown serves on the scientific advisory board for Alnylam Pharmaceuticals. The remaining authors have declared no conflict of interests.